The MoST Trial for OCCC

Ovarian Clear Cell Cancer Is Different: Dual Immunotherapy Signals Promise

Study: Phase II Trial of Combination Nivolumab plus Ipilimumab (PubMed ID: 40608313 / MoST-CIRCUIT) | Access Abstract via PubMed

The Bottom Line

Ovarian Clear Cell Cancer (OCCC) is a distinct, uncommon type of ovarian cancer—making up about 5% to 10% of cases in Western populations (and up to 15–20% in Asian cohorts). Unlike the more common serous types, clear cell tumours are notoriously resistant to standard platinum-based chemotherapy, leaving advanced cases with a poor 5-year survival rate of ~20%. Driven by unique molecular features—including underlying DNA repair deficiencies—OCCC is an ideal target for personalised immunotherapy. Early data from an Australian-led trial evaluating a dual drug combination (Nivolumab + Ipilimumab) shows encouraging response rates in this hard-to-treat group.

Disease Profile & Trial Snapshot

  • The Clinical Hurdle: Clear cell tumours often affect younger women and frequently arise alongside endometriosis. Standard chemotherapy drugs yield significantly lower response rates in advanced clear cell cases compared to typical ovarian cancers.

  • The Study Cohort: An Australian and New Zealand trial (MoST-CIRCUIT) evaluating 28 patients with advanced clear cell gynecologic cancers (24 ovarian, 4 endometrial) receiving combination immunotherapy.

  • How the Combination Works: The two drugs work as a team—Ipilimumab helps prime immune cells, while Nivolumab unblocks suppressed immune cells inside the tumour, allowing the patient's own immune system to attack cells with DNA repair defects.

  • Promising Early Signal: The trial reported a 54% overall response rate—a striking result for a cancer type that rarely responds to standard chemotherapy.

Clinical Reality Check: While these early responses are durable and encouraging, long-term survival endpoints (such as overall survival) have not yet fully matured. Larger phase III trials are required before this shifts routine standard of care.

What OCA Support Nurses Need to Know

  • Not All Ovarian Cancers Are the Same: Remind patients and families that "ovarian cancer" includes several distinct subtypes. Clear cell cancer behaves very differently from standard high-grade serous tumours—it needs tailored treatment strategies, and typical chemotherapy expectations do not apply.

  • Watching for Side Effects from Dual Immunotherapy: Combining two immunotherapy drugs carries a higher risk of immune-related side effects than a single drug (e.g., inflammation of the gut, lungs, liver, or endocrine system). Support nurses taking calls from patients on these trials should ask about symptoms like persistent diarrhea, unexplained fatigue, or sudden breathlessness.

  • Navigating Trial Discussions: For callers facing advanced or recurrent clear cell disease where standard chemo options are limited, nurses can encourage them to talk with their oncologist about biomarker testing (such as DNA repair/MSI status) and relevant clinical trial options.

Quick Tags:

#ClearCellCancer #Immunotherapy #Nivolumab #Ipilimumab #RareCancers #ClinicalTrials #PatientAdvocacy

Comments

Post a Comment

Popular posts from this blog

An impossible dream?

Image
Reducing ovarian cancer mortality through screening: an impossible dream? https://tinyurl.com/4524jh8f The history of screening tests for ovarian cancer is not good. Two huge trials; the UKCTOCS with  more than 200,000 recruits over 20 years and the PLCO trial with more than 3 million pathology samples  sho wed no benefit in terms of survival from ovarian cancer. This article addresses the stages of ovarian cancer using  an alternative approach called the clinical continuum,  which divides cancer into 3 phases ,  no disease, pre-clinical  (detectable disease) , and  clinical (overt cancer). Obviously for a screening test to be effective ,   cancer needs to be detected before the clinical  phase. However, ovarian cancer is unlike other cancer in that the precursor occurs in the fallopian tube and the re is an argument to say that ,  by the time ovarian cancer has occurred ,  it is always advanced and metastatic .   T his time in...
Read more

It’s not just your genotype

Image
Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization https://tinyurl.com/yhfkpwyb One of the perplexing aspects of ovarian cancer is why there is individual variation between those who do have cancer and those who don’t . It would be expected that women with high risk due to genetic mutation such as BR CA2 would all eventually succumb to breast or ovarian cancer. However, many (about 2 0%) , do not. This study suggests that brain structure and function may be part of the reason this is so. Magnetic Resonance Imaging (MRI) is able in a non-invasive way to identify different brain shapes and anatomy . Using data from the UK Biobank study it has bee n possible to identify 12 distinct varieties of brain anatomy which have an influence on ovarian cancer. Further investigation suggested distinct areas of brain cortex variation, with the right medial cortex being protective , and the right pre-cen...
Read more

Sugar doesn’t feed cancer

Image
Revisiting the Warburg-Based “Sugar Feeds Cancer” Hypothesis: A Critical Appraisal of Epidemiological, Experimental and Mechanistic Evidence https://tinyurl.com/3v2tysdt Many clinical care professionals receive queries from cancer patients about whether they should modify their diet to red u ce consumed sugar. This concern is based on a misunde r standing of some basic medical research known as the Warbur g effect. Research from 1956 show ed that cancer cells alter their metaboli sm to enable increased glucose uptake and increase energy production. A misunderstanding of this effect has led to incorrect dietary advice to cancer patients suggesting sugar restriction may be benefi cial. As a result, malnutrition , which is already a s i gnificant cause of morbidity for cancer patients , can be exacerbated . No hard evidence that low sugar diets alter survival exists. Some anecdotal reports suggest a slight correlation with risk. This study is a n appraisal of all credible re...
Read more